Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF) (2014 - 2026)

Collegium Pharmaceutical's Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $463000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 57.56% year-over-year to $463000.0 in Q1 2026; TTM through Mar 2026 was $3.6 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, up 8.45% from the prior year.
• Depreciation & Amortization (CF) eased to $463000.0 in Q1 2026 per COLL's latest filing, from $923000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q2 2025 and bottomed at $463000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $917000.0 (2024), against an average of $863588.2.
• Across the five-year window, Depreciation & Amortization (CF) surged 94.58% in 2022 and slumped 57.56% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $825000.0 in 2022, then climbed by 15.03% to $949000.0 in 2023, then rose by 9.69% to $1.0 million in 2024, then slipped by 11.34% to $923000.0 in 2025, then plunged by 49.84% to $463000.0 in 2026.
• Per Business Quant, the three latest COLL Depreciation & Amortization (CF) figures stand at $463000.0 (Q1 2026), $923000.0 (Q4 2025), and $1.0 million (Q3 2025).